The Influence of Zoledronate and Teriparatide on Gamma Delta T Cells in Mice

Overview

Journal J Dent Sci

Specialty Dentistry

Date 2019 Mar 22

PMID 30895072

Citations 3

Authors

Eiki Yamachika

Yuichi Matsui

Masakazu Matsubara

Tatsushi Matsumura

Naoki Nakata

Norifumi Moritani

Atsushi Ikeda

Hidetsugu Tsujigiwa

Naoya Ohara

Seiji Iida

Affiliations

Soon will be listed here.

Abstract

Background/purpose: Few studies have investigated the possibility that bisphosphonate-related osteonecrosis of the jaw (BRONJ) might reflect an immune response; however, gamma delta T cells have been shown to significantly decline in the blood of BRONJ patients. Additionally, there have been some reports of teriparatide usage for the treatment of BRONJ. In this study, we compared the effects of zoledronate and teriparatide on lymphocyte populations and inflammatory cytokine production in mice.

Materials And Methods: Thirty female ICR mice were divided into three groups (n = 10 each): a vehicle, a zoledronate, and a teriparatide group. Drugs were administered for 8 weeks in each group. Lymphocytes in the blood and thymus were analyzed and femurs were used for histological observation and lymphocytes analysis of bone marrow. Cytokines were measured in separated serum using Milliplex multiplex immunoassay analysis.

Results: Zoledronate decreased the T cell number in the bone marrow. Additionally, serum levels of interleukin (IL)-2, IL-7, IL-12, IL-15 and RANTES, which are cytokines that affect T cell activation, differentiation and/or proliferation, were significantly lower in zoledronate treated mice. Conversely, teriparatide treatment induced an increase in gamma delta T cells in peripheral blood.

Conclusion: Gamma delta T cells in the bone marrow are expected to decrease with zoledronate treatment and increase with teriparatide treatment. If BRONJ involves a loss of gamma delta T cells in the circulation or bone marrow, then the increase in gamma delta T cells that is induced by teriparatide may account for its ability to resolve BRONJ.

Citing Articles

Preparation, identification and molecular docking study of novel osteoblast proliferation-promoting peptides from yak () bones.

Ye M, Jia W, Zhang C, Shen Q, Zhu L, Wang L RSC Adv. 2022; 9(26):14627-14637.

PMID: 35516346 PMC: 9064140. DOI: 10.1039/c9ra00945k.

Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Aguirre J, Castillo E, Kimmel D Bone. 2021; 153:116184.

PMID: 34520898 PMC: 8743993. DOI: 10.1016/j.bone.2021.116184.

The Antiosteoporosis Effects of Yishen Bugu Ye Based on Its Regulation on the Differentiation of Osteoblast and Osteoclast.

Li Y, Zhang Y, Meng W, Li Y, Huang T, Wang D Biomed Res Int. 2020; 2020:9467683.

PMID: 32149147 PMC: 7054773. DOI: 10.1155/2020/9467683.

References

Kunzmann V, Bauer E, Wilhelm M . Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999; 340(9):737-8. DOI: 10.1056/NEJM199903043400914. View

Berenson J, Lipton A . Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med. 1999; 50:237-48. DOI: 10.1146/annurev.med.50.1.237. View

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

Patschan D, Loddenkemper K, Buttgereit F . Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 2001; 29(6):498-505. DOI: 10.1016/s8756-3282(01)00610-x. View

Faucheux C, Horton M, Price J . Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast.... J Bone Miner Res. 2002; 17(3):455-64. DOI: 10.1359/jbmr.2002.17.3.455. View

Toraldo G, Roggia C, Qian W, Pacifici R, Weitzmann M . IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A. 2002; 100(1):125-30. PMC: 140902. DOI: 10.1073/pnas.0136772100. View

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

Ramaswamy B, Shapiro C . Bisphosphonates in the prevention and treatment of bone metastases. Oncology (Williston Park). 2003; 17(9):1261-70. View

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D . Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88(6):2095-105. PMC: 295810. DOI: 10.1172/JCI115539. View

10.

Harper R, Fung E . Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg. 2007; 65(3):573-80. DOI: 10.1016/j.joms.2006.10.076. View

11.

Leupin O, Kramer I, Collette N, Loots G, Natt F, Kneissel M . Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res. 2007; 22(12):1957-67. PMC: 2882185. DOI: 10.1359/jbmr.070804. View

12.

Lipton A . Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone. Cancer Treat Rev. 2008; 34 Suppl 1:S25-30. DOI: 10.1016/j.ctrv.2008.03.008. View

13.

Wimalawansa S . Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf. 2008; 7(4):491-512. DOI: 10.1517/14740338.7.4.491. View

14.

Terauchi M, Li J, Bedi B, Baek K, Tawfeek H, Galley S . T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009; 10(3):229-40. PMC: 2751855. DOI: 10.1016/j.cmet.2009.07.010. View

15.

Greenberger S, Boscolo E, Adini I, Mulliken J, Bischoff J . Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010; 362(11):1005-13. PMC: 2845924. DOI: 10.1056/NEJMoa0903036. View

16.

Genetos D, Toupadakis C, Raheja L, Wong A, Papanicolaou S, Fyhrie D . Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem. 2010; 110(2):457-67. PMC: 2881162. DOI: 10.1002/jcb.22559. View

17.

Drake M, Srinivasan B, Modder U, Peterson J, McCready L, Riggs B . Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010; 95(11):5056-62. PMC: 2968729. DOI: 10.1210/jc.2010-0720. View

18.

Tipton D, Seshul B, Dabbous M . Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. J Periodontal Res. 2010; 46(1):39-47. DOI: 10.1111/j.1600-0765.2010.01306.x. View

19.

Tawfeek H, Bedi B, Li J, Adams J, Kobayashi T, Weitzmann M . Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One. 2010; 5(8):e12290. PMC: 2924900. DOI: 10.1371/journal.pone.0012290. View

20.

Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M . Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res. 2011; 27(2):360-73. DOI: 10.1002/jbmr.1492. View